|
US2020181153A1
|
|
Imidazopyridazinone compounds and uses thereof
|
|
WO2019245910A1
|
|
Triazine compounds and uses thereof
|
|
AU2019213843A1
|
|
Combination of STING agonist and IL-15/IL15-Ra for the treatment of cancer
|
|
EP3681888A1
|
|
Pyrazolopyrimidinone compounds and uses thereof
|
|
WO2018026717A1
|
|
Protein expression enhancer sequences and use thereof
|
|
EP3507367A1
|
|
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
US2018369268A1
|
|
Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
|
|
AU2016247894A1
|
|
Immunogenic fusion proteins for the treatment of cancer
|
|
KR20180002640A
|
|
Epidermal growth factor receptor variant III-mesothelin fusions and methods of using same
|
|
AU2016229146A1
|
|
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
|
US2015125485A1
|
|
Methods and compositions using listeria for enhancing immunogenicity by prime boost
|
|
US2014341976A1
|
|
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
WO2014189805A1
|
|
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
CN105188373A
|
|
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
|
MX2015008329A
|
|
Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof.
|
|
CN105008381A
|
|
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
EP2576791A1
|
|
Methods and compositions using listeria for adjuvant treatment of cancer
|
